Status:
COMPLETED
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
Lead Sponsor:
The University of Texas Health Science Center, Houston
Conditions:
Hemophilia A
Eligibility:
MALE
1-99 years
Brief Summary
To correlate the Human Leukocyte Antigen type and genetic defect with hemophilia A.
Detailed Description
One of the most serious complications of treatment in patients with hemophilia A or hemophilia B is the development of an inhibitor, which is an antibody that neutralizes the factor VIII or IX coagula...
Eligibility Criteria
Inclusion
- Severe Hemophilia A with an inhibitor level of 0.6 B.U. or higher
Exclusion
- Severe Hemophilia A with a negative inhibitor
Key Trial Info
Start Date :
August 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT00178607
Start Date
August 1 2002
End Date
October 1 2015
Last Update
May 12 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Univeristy of Texas Health Science Center at Houston
Houston, Texas, United States, 77030